NEW YORK (GenomeWeb) – The University of Texas Southwestern Medical Center has exclusively licensed an exosome-based diagnostic technology to Peregrine Pharmaceuticals.

Financial and other terms of the agreement were not disclosed.

Peregrine VP of Preclinical Research Jeff Hutchins said in a statement that the technology could be used as a companion diagnostic in the development of the firm's lead cancer immunotherapy candidate bavituximab, as well as a more general test for cancer detection and monitoring.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.